» Articles » PMID: 38852068

The American Association of Tissue Banks Tissue Donor Screening for Mycobacterium Tuberculosis-Recommended Criteria and Literature Review

Abstract

After two multistate outbreaks of allograft tissue-transmitted tuberculosis (TB) due to viable bone, evidence-based donor screening criteria were developed to decrease the risk of transmission to recipients. Exclusionary criteria, commentary, and references supporting the criteria are provided, based on literature search and expert opinion. Both exposure and reactivation risk factors were considered, either for absolute exclusion or for exclusion in combination with multiple risk factors. A criteria subset was devised for tissues containing viable cells. Risk factors for consideration included exposure (e.g., geographic birth and residence, travel, homelessness, incarceration, healthcare, and workplace) and reactivation (e.g., kidney disease, liver disease, history of transplantation, immunosuppressive medications, and age). Additional donor considerations include the possibility of sepsis and chronic illness. Donor screening criteria represent minimal criteria for exclusion and do not completely exclude all possible donor TB risks. Additional measures to reduce transmission risk, such as donor and product testing, are discussed but not included in the recommendations. Careful donor evaluation is critical to tissue safety.

Citing Articles

Mycobacterium tuberculosis Infection After Grafting of Infected Bone: A Case Series of Four Patients.

Ajibola O, Wolfe A, Ali J Cureus. 2024; 16(8):e66603.

PMID: 39258071 PMC: 11385073. DOI: 10.7759/cureus.66603.


The American Association of Tissue Banks tissue donor screening for Mycobacterium tuberculosis-Recommended criteria and literature review.

Greenwald M, Edwards N, Eastlund D, Gurevich I, Ho A, Khalife G Transpl Infect Dis. 2024; 26 Suppl 1:e14294.

PMID: 38852068 PMC: 11578281. DOI: 10.1111/tid.14294.

References
1.
Abad C, Razonable R . Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases. Clin Transplant. 2018; 32(6):e13259. DOI: 10.1111/ctr.13259. View

2.
Yan M, Puyat J, Shulha H, Clark E, Levin A, Johnston J . Risk of tuberculosis associated with chronic kidney disease: a population-based analysis. Nephrol Dial Transplant. 2021; 37(1):197-198. DOI: 10.1093/ndt/gfab222. View

3.
Sipeki N, Antal-Szalmas P, Lakatos P, Papp M . Immune dysfunction in cirrhosis. World J Gastroenterol. 2014; 20(10):2564-77. PMC: 3949265. DOI: 10.3748/wjg.v20.i10.2564. View

4.
Ferraris D, Miggiano R, Rossi F, Rizzi M . Mycobacterium tuberculosis Molecular Determinants of Infection, Survival Strategies, and Vulnerable Targets. Pathogens. 2018; 7(1). PMC: 5874743. DOI: 10.3390/pathogens7010017. View

5.
Lonnroth K, Roglic G, Harries A . Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol. 2014; 2(9):730-9. DOI: 10.1016/S2213-8587(14)70109-3. View